RPG Life Sciences Q1 FY27 results: Revenue up 15.8%, EBITDA margin at 24.5%

Ebitda Margin ExpansionResults View source PDF Explain this filing

RPGLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.0%Reaction day

₹2906.00

prior close

₹2950.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.5%-2.5% vs market

Pharmaceuticals peers, median of 160sector+0.8%-2.8% vs sector

On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250 and 2.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.5

10m

-3.4

15m

-4.9

30m

-1.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.0+0.5-2.5+0.8-2.8

Next day

-4.1-0.1-4.0+0.0-4.1

-4.7+1.0-5.7+0.1-4.8

-5.1+2.3-7.4+0.6-5.7

-6.0+2.8-8.7+1.0-7.0

-6.2+4.1-10.3+0.6-6.9

-8.8+4.5-13.3+1.6-10.4

15d

-8.8+4.8-13.6+0.5-9.3

-9.0+6.4-15.4+2.1-11.1

+6.8+5.5+1.3+3.3+3.5

+3.5pendingpending-2.2+5.8

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

RPG Life Sciences posted Q1 FY27 revenue of about Rs 195.7 crore, up 15.8% year-on-year. EBITDA grew 17.9% to Rs 48 crore with margins expanding 40 basis points to 24.5%. Domestic Formulations grew 14.8%, beating the Indian pharma market growth of 11.6%. API business surged 35.6%, International Formulations rose 7.7%. Company entered the Top 50 Indian Pharma Companies ranking in June 2026.

Likely market impact

Strong start to FY27 with margin expansion and broad-based growth. Top 50 pharma milestone boosts visibility and credibility.